---
id: mount-sinai-ai-center
slug: mount-sinai-ai-center
entity_type: research
status: operational
data_completeness: high
last_researched: 2025-01-27
research_category: academic_institution
researcher: AI Assistant
version: 3.1
name: AI Small Molecule Drug Discovery Center
description: Integration of artificial intelligence with traditional drug discovery methods to accelerate the development of new small-molecule therapeutics for complex diseases. The center employs a hybrid AI approach that integrates generative AI, predictive modeling, and traditional computational methods to enable comprehensive drug discovery across previously siloed datasets.
mission: To integrate artificial intelligence with traditional drug discovery methods to identify and design new small-molecule therapeutics with unprecedented speed and precision. The center aims to accelerate the development of treatments for complex diseases including cancer, neurological diseases, and metabolic disorders by leveraging generative AI, predictive modeling, and comprehensive data integration across previously siloed datasets.
entity_data:
  name: AI Small Molecule Drug Discovery Center
  status: operational
  results: Center launched in April 2025, actively developing AI-driven drug discovery capabilities. Early results and validation studies are in progress.
  website: "https://icahn.mssm.edu/research/ai-drug-discovery-center"
  objectives:
  - Design novel drug-like molecules using generative AI
  - Optimize existing compounds to enhance their efficacy and safety
  - Predict drug-target interactions to repurpose known drugs or natural products for new indications
  - Integrate data across previously siloed datasets to enable comprehensive drug discovery
  start_date: 2025-04-02
  description: Integration of artificial intelligence with traditional drug discovery methods to accelerate the development of new small-molecule therapeutics for complex diseases
  launch_date: 2025-04-02
  methodology: Hybrid AI approach integrating generative AI, predictive modeling, and traditional computational methods
  research_institution:
  name: Icahn School of Medicine at Mount Sinai
  building: Annenberg Building, Floor 19, Room 60A
  location:
  city: New York
  state: New York
  address: 1468 Madison Avenue, New York, NY 10029
  country: USA
taxonomy:
  geography: USA
  ai_approach:
  - Generative AI
  - Supervised Learning
  ai_technology:
  - Generative AI
  - Graph Neural Networks
  - Ensemble Methods
  primary_focus:
  - AI-Driven Drug Discovery
  aging_approach:
  - Molecule Design
  target_biology:
  - Cancer/Oncology
  - General Aging/Longevity
  ai_architecture:
  - Graph Neural Networks
  ai_specialization:
  - Ensemble Methods
  development_stage: Operational
  therapeutic_modality:
  - Small Molecules
organizations:
  -
    name: NVIDIA
    role: partner
    org_type: company
    legal_name: NVIDIA Corporation
    website: "https://www.nvidia.com"
    status: operational
    role_description: Technology partner
    contribution_description: Three-year collaboration to harness AI for genomic discovery using large language model technology
  -
    name: ARC Innovation at Sheba Medical Center
    role: collaborator
    org_type: institution
    status: operational
    role_description: Research collaborator
    contribution_description: Three-year collaboration with NVIDIA to harness AI for genomic discovery, aiming to decode unexplored parts of the human genome
  -
    name: IPGaia Inc.
    role: partner
    org_type: company
    status: operational
    role_description: Industry partner
    contribution_description: "Collaborative Research and Development Agreement to incorporate promising drug target leads from Mount Sinai into IPGaia's drug discovery platform"
  -
    name: Icahn School of Medicine at Mount Sinai
    role: primary
    org_type: institution
    legal_name: Icahn School of Medicine at Mount Sinai
    website: "https://icahn.mssm.edu/"
    status: operational
    role_description: Primary research institution
    contribution_description: Provides research infrastructure, faculty support, laboratory facilities, computational resources (Minerva HPC system), administrative support, and internal funding for the AI Small Molecule Drug Discovery Center
links:
  -
    url: "https://icahn.mssm.edu/research/ddi/capabilities/drug-discovery"
    type: website
    title: Drug Discovery Capabilities | Icahn School of Medicine
  -
    url: "https://www.nature.com/collections/ajgfabehdd"
    type: publication
    title: "Nature Collection: AI and Small Molecule Drug Discovery"
  -
    url: "https://www.mountsinai.org/about/newsroom/2025/mount-sinai-researchers-develop-novel-computational-approach-for-identifying-synergistic-drug-combinations"
    type: press_release
    title: Mount Sinai Researchers Develop Novel Computational Approach for Identifying Synergistic Drug Combinations
  -
    url: "https://icahn.mssm.edu/profiles/girish-nadkarni"
    type: profile
    title: Girish N. Nadkarni Profile | Icahn School of Medicine
  -
    url: "https://icahn.mssm.edu/profiles/marta-filizola"
    type: profile
    title: Marta Filizola Profile | Icahn School of Medicine
  -
    url: "https://icahn.mssm.edu/profiles/ming-ming-zhou"
    type: profile
    title: Ming-Ming Zhou Profile | Icahn School of Medicine
  -
    url: "https://icahn.mssm.edu/profiles/jian-jin"
    type: profile
    title: Jian Jin Profile | Icahn School of Medicine
  -
    url: "https://icahn.mssm.edu/profiles/avner-schlessinger"
    type: profile
    title: Avner Schlessinger Profile | Icahn School of Medicine
  -
    url: "https://icahn.mssm.edu/research/ddi/capabilities/drug-discovery/resources"
    type: website
    title: Drug Discovery Resources | Icahn School of Medicine
  -
    url: "https://www.mountsinai.org/about/newsroom/2023/icahn-school-of-medicine-at-mount-sinai-secures-five-million-nih-grant-for-cutting-edge-cancer-target-discovery-and-development-center"
    type: press_release
    title: Icahn School of Medicine at Mount Sinai Secures Five Million NIH Grant for Cutting-Edge Cancer Target Discovery and Development Center
  -
    url: "https://www.mountsinai.org/about/newsroom/2025/mount-sinai-receives-8-million-from-dataphilanthropy-to-accelerate-drug-discovery-for-cadasil-and-related-brain-disorders"
    type: press_release
    title: Mount Sinai Receives $8 Million from DataPhilanthropy to Accelerate Drug Discovery for CADASIL and Related Brain Disorders
  -
    url: "https://www.mountsinai.org/about/newsroom/2025/arc-at-sheba-medical-center-and-mount-sinai-launch-collaboration-with-nvidia-to-crack-the-hidden-code-of-the-human-genome-through-ai"
    type: press_release
    title: ARC at Sheba Medical Center and Mount Sinai Launch Collaboration with NVIDIA to Crack the Hidden Code of the Human Genome Through AI
  -
    url: "https://www.mountsinai.org/about/newsroom/2024/ipgaia-and-the-icahn-school-of-medicine-at-mount-sinai-announce-comprehensive-collaborative-research-and-development-agreement"
    type: press_release
    title: IPGaia and the Icahn School of Medicine at Mount Sinai Announce Comprehensive Collaborative Research and Development Agreement
  -
    url: "https://icahn.mssm.edu/about/artificial-intelligence/research"
    type: website
    title: Health and Medical AI Research | Icahn School of Medicine
  -
    url: "https://icahn.mssm.edu/research/ai-drug-discovery-center"
    type: website
    title: AI Small Molecule Drug Discovery Center | Icahn School of Medicine
  -
    url: "https://www.mountsinai.org/about/newsroom/2025/mount-sinai-launches-ai-small-molecule-drug-discovery-center"
    type: press_release
    title: Mount Sinai Launches AI Small Molecule Drug Discovery Center
---

# AI Small Molecule Drug Discovery Center

## Description

Integration of artificial intelligence with traditional drug discovery methods to accelerate the development of new small-molecule therapeutics for complex diseases. The center employs a hybrid AI approach that integrates generative AI, predictive modeling, and traditional computational methods to enable comprehensive drug discovery across previously siloed datasets.

## Mission

To integrate artificial intelligence with traditional drug discovery methods to identify and design new small-molecule therapeutics with unprecedented speed and precision. The center aims to accelerate the development of treatments for complex diseases including cancer, neurological diseases, and metabolic disorders by leveraging generative AI, predictive modeling, and comprehensive data integration across previously siloed datasets.

## Project Information

**Start Date**: 2025-04-02
**Objectives**: Design novel drug-like molecules using generative AI,Optimize existing compounds to enhance their efficacy and safety,Predict drug-target interactions to repurpose known drugs or natural products for new indications,Integrate data across previously siloed datasets to enable comprehensive drug discovery
**Methodology**: Hybrid AI approach integrating generative AI, predictive modeling, and traditional computational methods
**Results**: Center launched in April 2025, actively developing AI-driven drug discovery capabilities. Early results and validation studies are in progress.

## AI Methods

- Hybrid AI Models
- Generative AI for molecule design
- Predictive modeling for drug-target interactions
- Machine learning for compound optimization
- Data integration across silos

## Scientific Background

```yaml
related_research:
  iDOMO_tool:
  name: iDOMO (Improved Drug Optimization Model)
  relevance: "Demonstrates Mount Sinai's capability in developing AI tools for drug discovery, potentially informing the center's approach to combination therapy discovery"
  application: Successfully identified promising drug combinations for triple-negative breast cancer, validated through in vitro experiments
  description: Computational tool developed by Mount Sinai researchers in February 2025 for predicting drug synergy and accelerating development of combination therapies for complex diseases
historical_context:
  industry_context: "The center operates in a landscape where major players like Insilico Medicine, Atomwise, Recursion Pharmaceuticals, and others have demonstrated the potential of AI in drug discovery. Mount Sinai's approach emphasizes academic research, open collaboration, and integration with traditional drug discovery infrastructure."
  mount_sinai_contribution: "Mount Sinai's AI Small Molecule Drug Discovery Center represents the latest evolution in AI-driven drug discovery, focusing on hybrid approaches that integrate generative AI, predictive modeling, and traditional computational methods to address the challenge of data silos in pharmaceutical research."
  ai_drug_discovery_evolution: AI in drug discovery has evolved significantly from early rule-based systems (1980s-1990s) to machine learning approaches (2000s-2010s) to deep learning and generative AI (2020s). The field accelerated dramatically in the 2020s with advances in transformer architectures, graph neural networks, and diffusion models, enabling de novo molecule design and comprehensive data integration.
comparison_with_existing_methods:
  traditional_drug_discovery:
  lead_optimization:
  description: Traditional lead optimization requires extensive experimental testing of compound libraries, taking years and significant resources
  ai_advantage: AI-driven optimization predicts ADMET properties and structure-activity relationships, reducing the number of compounds that need experimental validation
  structure_based_design:
  description: Traditional structure-based design relies on docking and MD simulations, which are computationally expensive and time-consuming
  ai_advantage: AI models provide rapid binding affinity predictions and guide docking calculations, enabling faster iteration and optimization cycles
  high_throughput_screening:
  description: Traditional HTS screens 1-3 million compounds over months, with high costs ($0.10-1.00 per compound) and low hit rates (0.01-0.1%)
  ai_advantage: AI-accelerated virtual screening can pre-filter millions of compounds in days, reducing costs and focusing experimental resources on high-probability candidates
```

## Infrastructure

```yaml
software:
  - AutoDock, AutoDock VINA (molecular docking)
  - eHiTs, DOCK, Gold (structure-based drug design)
  - DockRes, MODELLER (protein structure modeling)
  - SiteHound, fPocket (binding site prediction)
  - PyTorch, TensorFlow (deep learning frameworks)
  - RDKit, OpenEye (molecular informatics)
  - Custom AI models and pipelines
computing:
  - High-performance workstations and servers for molecular modeling and graphics
  - Minerva high-performance computing system for virtual screening of millions of compounds in days
  - GPU clusters for deep learning model training and inference
  - Cloud computing resources for scalable AI workloads
databases:
  - Small molecule compound libraries containing over 20 million commercially available compounds
  - Active compounds database for algorithm development and validation
  - Drug-target interaction databases
  - Molecular structure databases (PubChem, ChEMBL, ZINC)
  - Biological activity databases
  - Clinical trial and genomic datasets
```

## Lessons Learned

### Achievements

- Successfully launched AI Small Molecule Drug Discovery Center in April 2025
- Established comprehensive AI infrastructure with Minerva HPC system and 20M+ compound libraries
- Secured major external funding ($8M DataPhilanthropy grant, $5M NCI grant)
- Formed strategic partnerships with IPGaia Inc., NVIDIA, and ARC Innovation
- Developed hybrid AI approach integrating generative AI, predictive modeling, and traditional methods
- Created educational programs (hackathons, summer research programs, seminars) to train next generation of medical AI researchers

### Implications

- Hybrid AI approach enables comprehensive drug discovery across previously siloed datasets
- AI-accelerated virtual screening can dramatically reduce time and costs compared to traditional methods
- Generative AI enables discovery of novel compounds not present in existing libraries
- Data integration is critical for maximizing the value of AI in drug discovery
- Academic institutions can play important role in AI drug discovery through open collaboration and research

### Challenges

- Center is in early stages, comprehensive validation results not yet available
- AI model accuracy depends on training data quality and target complexity
- AI predictions require experimental validation, not all predictions will be confirmed
- Data integration effectiveness depends on quality and consistency of source datasets
- Breaking down data silos across molecular, biological, and clinical domains requires significant effort

### Impact on Field

Mount Sinai's AI Small Molecule Drug Discovery Center provides foundational AI infrastructure for longevity research by enabling scalable data integration across previously siloed datasets. While not exclusively focused on aging, the center's capabilities in small molecule discovery and data integration can support longevity research by enabling faster identification and optimization of compounds targeting aging-related pathways and diseases.

## Organizations

### NVIDIA
**Legal Name**: NVIDIA Corporation
**Role in Project**: partner
**Role Description**: Technology partner
**Contribution**: Three-year collaboration to harness AI for genomic discovery using large language model technology
**Organization Type**: company
**Status**: operational
**Website**: https://www.nvidia.com
**Description**: AI computing infrastructure partner for Genesis Mission.
**Focus**: AI computing infrastructure, GPU technology

### ARC Innovation at Sheba Medical Center
**Role in Project**: collaborator
**Role Description**: Research collaborator
**Contribution**: Three-year collaboration with NVIDIA to harness AI for genomic discovery, aiming to decode unexplored parts of the human genome
**Organization Type**: institution
**Status**: operational
**Description**: ARC Innovation at Sheba Medical Center collaborating with Mount Sinai and NVIDIA on AI genomic discovery

### IPGaia Inc.
**Role in Project**: partner
**Role Description**: Industry partner
**Contribution**: Collaborative Research and Development Agreement to incorporate promising drug target leads from Mount Sinai into IPGaia's drug discovery platform
**Organization Type**: company
**Status**: operational
**Description**: Biotechnology company collaborating with Mount Sinai on drug discovery platform development

### Icahn School of Medicine at Mount Sinai
**Role in Project**: primary
**Role Description**: Primary research institution
**Contribution**: Provides research infrastructure, faculty support, laboratory facilities, computational resources (Minerva HPC system), administrative support, and internal funding for the AI Small Molecule Drug Discovery Center
**Organization Type**: institution
**Status**: operational
**Website**: https://icahn.mssm.edu/
**Description**: Medical school in New York, affiliation of clinical advisor
**Focus**: Medical education, Research, Dermatology

## Locations

### Annenberg Building, Floor 19, Room 60A
**Type**: institution
**Address**: 1468 Madison Avenue, New York, NY 10029
**City**: New York
**State/Region**: New York
**Country**: USA
**Organizations**: Icahn School of Medicine at Mount Sinai

## Key People

### Girish N. Nadkarni
**Title**: MD, Professor and Chair of Artificial Intelligence and Human Health, Professor of Medicine (Nephrology), Professor of Urology
**Participation Type**: advisor
**Role in Project**: Advisory Board Member
**Participation Period**: 2025-ongoing
**Contribution**: Advisory Board Member providing strategic guidance on AI applications in healthcare and integration with clinical research. Professor and Chair of Artificial Intelligence and Human Health
**Expertise**: AI and human health, Medicine, Nephrology, Urology, Clinical research, Healthcare AI
**Biography**: Professor and Chair of Artificial Intelligence and Human Health. Provides strategic guidance on AI applications in healthcare and integration with clinical research.
**Profile**: https://icahn.mssm.edu/profiles/girish-nadkarni

### Marta Filizola
**Title**: PhD, Dean for the Graduate School of Biomedical Sciences, Professor of Pharmacological Sciences, Neuroscience, and Artificial Intelligence and Human Health
**Participation Type**: advisor
**Role in Project**: Advisory Board Member
**Participation Period**: 2025-ongoing
**Contribution**: Advisory Board Member providing strategic guidance on AI research integration and educational programs. Dean for the Graduate School of Biomedical Sciences
**Expertise**: AI and human health, Pharmacological sciences, Neuroscience, Computational biology, Educational programs
**Biography**: Dean for the Graduate School of Biomedical Sciences and Professor with expertise in AI and human health. Provides strategic guidance on AI research integration and educational programs.
**Profile**: https://icahn.mssm.edu/profiles/marta-filizola

### Ming-Ming Zhou
**Title**: PhD, Professor and Chair of Pharmacological Sciences, Professor of Oncological Sciences, Co-Director of Drug Discovery Institute
**Participation Type**: advisor
**Role in Project**: Advisory Board Member
**Participation Period**: 2025-ongoing
**Contribution**: Advisory Board Member providing strategic guidance on drug discovery infrastructure and research direction. Professor and Chair of Pharmacological Sciences, Co-Director of Drug Discovery Institute
**Expertise**: Pharmacological sciences, Drug discovery, Structural biology, Medicinal chemistry
**Biography**: Professor and Chair of Pharmacological Sciences, Co-Director of Drug Discovery Institute. Provides strategic guidance on drug discovery infrastructure and research direction.
**Profile**: https://icahn.mssm.edu/profiles/ming-ming-zhou

### Jian Jin
**Title**: PhD, Professor of Oncological Sciences, Pharmacological Sciences, and Neuroscience
**Participation Type**: advisor
**Role in Project**: Advisory Board Member
**Participation Period**: 2025-ongoing
**Contribution**: Advisory Board Member providing strategic guidance on drug discovery research programs, with expertise in oncological sciences, pharmacological sciences, and neuroscience
**Expertise**: Oncological sciences, Pharmacological sciences, Neuroscience, Drug discovery
**Biography**: Professor with expertise in oncological sciences, pharmacological sciences, and neuroscience. Provides strategic guidance on drug discovery research programs.
**Profile**: https://icahn.mssm.edu/profiles/jian-jin

### Avner Schlessinger
**Title**: PhD, Professor of Pharmacological Sciences
**Participation Type**: pi
**Role in Project**: Director, Principal Investigator
**Participation Period**: 2025-ongoing
**Responsibilities**:
- Overall center leadership and research direction
- Strategic planning and resource allocation
- Partnership development and management
- Grant management and funding coordination
- Research program oversight
**Contribution**: Director of the AI Small Molecule Drug Discovery Center, responsible for overall center leadership, strategic direction, and research program coordination
**Expertise**: Computational drug discovery, Structural biology, Pharmacological sciences, AI-driven drug discovery
**Biography**: Professor of Pharmacological Sciences and Director of the AI Small Molecule Drug Discovery Center. Associate Director of the Mount Sinai Center for Therapeutics Discovery. Expert in computational drug discovery and structural biology.
**Profile**: https://icahn.mssm.edu/profiles/avner-schlessinger
**Email**: avner.schlessinger@mssm.edu

## Links

### [Drug Discovery Capabilities | Icahn School of Medicine](https://icahn.mssm.edu/research/ddi/capabilities/drug-discovery)
**Type**: website
**Relevance**: secondary
**Category**: resource
**Relationship Description**: Overview of drug discovery capabilities and resources at Mount Sinai
**Publisher**: Icahn School of Medicine at Mount Sinai
**Description**: Overview of drug discovery capabilities and resources at Mount Sinai

### [Nature Collection: AI and Small Molecule Drug Discovery](https://www.nature.com/collections/ajgfabehdd)
**Type**: publication
**Relevance**: secondary
**Category**: publication
**Relationship Description**: Nature collection highlighting the transformative impact of AI and machine learning techniques on modern drug design, providing context for the field
**Publisher**: Nature
**Description**: Nature collection highlighting the transformative impact of AI and machine learning techniques on modern drug design, providing context for the field

### [Mount Sinai Researchers Develop Novel Computational Approach for Identifying Synergistic Drug Combinations](https://www.mountsinai.org/about/newsroom/2025/mount-sinai-researchers-develop-novel-computational-approach-for-identifying-synergistic-drug-combinations)
**Type**: press_release
**Relevance**: secondary
**Category**: research
**Relationship Description**: Press release about iDOMO computational tool for drug synergy prediction, demonstrating Mount Sinai's AI drug discovery capabilities
**Publisher**: Mount Sinai Health System
**Publication Date**: 2025-02-01
**Description**: Press release about iDOMO computational tool for drug synergy prediction, demonstrating Mount Sinai's AI drug discovery capabilities

### [Girish N. Nadkarni Profile | Icahn School of Medicine](https://icahn.mssm.edu/profiles/girish-nadkarni)
**Type**: profile
**Relevance**: secondary
**Category**: profile
**Relationship Description**: Profile page for advisory board member Girish N. Nadkarni
**Publisher**: Icahn School of Medicine at Mount Sinai
**Description**: Profile page for advisory board member Girish N. Nadkarni

### [Marta Filizola Profile | Icahn School of Medicine](https://icahn.mssm.edu/profiles/marta-filizola)
**Type**: profile
**Relevance**: secondary
**Category**: profile
**Relationship Description**: Profile page for advisory board member Marta Filizola
**Publisher**: Icahn School of Medicine at Mount Sinai
**Description**: Profile page for advisory board member Marta Filizola

### [Ming-Ming Zhou Profile | Icahn School of Medicine](https://icahn.mssm.edu/profiles/ming-ming-zhou)
**Type**: profile
**Relevance**: secondary
**Category**: profile
**Relationship Description**: Profile page for advisory board member Ming-Ming Zhou
**Publisher**: Icahn School of Medicine at Mount Sinai
**Description**: Profile page for advisory board member Ming-Ming Zhou

### [Jian Jin Profile | Icahn School of Medicine](https://icahn.mssm.edu/profiles/jian-jin)
**Type**: profile
**Relevance**: secondary
**Category**: profile
**Relationship Description**: Profile page for advisory board member Jian Jin
**Publisher**: Icahn School of Medicine at Mount Sinai
**Description**: Profile page for advisory board member Jian Jin

### [Avner Schlessinger Profile | Icahn School of Medicine](https://icahn.mssm.edu/profiles/avner-schlessinger)
**Type**: profile
**Relevance**: secondary
**Category**: profile
**Relationship Description**: Profile page for center director Avner Schlessinger
**Publisher**: Icahn School of Medicine at Mount Sinai
**Description**: Profile page for center director Avner Schlessinger

### [Drug Discovery Resources | Icahn School of Medicine](https://icahn.mssm.edu/research/ddi/capabilities/drug-discovery/resources)
**Type**: website
**Relevance**: secondary
**Category**: resource
**Relationship Description**: Information about drug discovery resources and capabilities at Mount Sinai
**Publisher**: Icahn School of Medicine at Mount Sinai
**Description**: Information about drug discovery resources and capabilities at Mount Sinai

### [Icahn School of Medicine at Mount Sinai Secures Five Million NIH Grant for Cutting-Edge Cancer Target Discovery and Development Center](https://www.mountsinai.org/about/newsroom/2023/icahn-school-of-medicine-at-mount-sinai-secures-five-million-nih-grant-for-cutting-edge-cancer-target-discovery-and-development-center)
**Type**: press_release
**Relevance**: secondary
**Category**: funding
**Relationship Description**: Press release about NCI grant, may support related drug discovery infrastructure
**Publisher**: Mount Sinai Health System
**Publication Date**: 2023-11-15
**Description**: Press release about NCI grant, may support related drug discovery infrastructure

### [Mount Sinai Receives $8 Million from DataPhilanthropy to Accelerate Drug Discovery for CADASIL and Related Brain Disorders](https://www.mountsinai.org/about/newsroom/2025/mount-sinai-receives-8-million-from-dataphilanthropy-to-accelerate-drug-discovery-for-cadasil-and-related-brain-disorders)
**Type**: press_release
**Relevance**: secondary
**Category**: funding
**Relationship Description**: Press release about DataPhilanthropy grant funding
**Publisher**: Mount Sinai Health System
**Publication Date**: 2025-09-17
**Description**: Press release about DataPhilanthropy grant funding

### [ARC at Sheba Medical Center and Mount Sinai Launch Collaboration with NVIDIA to Crack the Hidden Code of the Human Genome Through AI](https://www.mountsinai.org/about/newsroom/2025/arc-at-sheba-medical-center-and-mount-sinai-launch-collaboration-with-nvidia-to-crack-the-hidden-code-of-the-human-genome-through-ai)
**Type**: press_release
**Relevance**: secondary
**Category**: partnership
**Relationship Description**: Press release about collaboration with NVIDIA and ARC Innovation
**Publisher**: Mount Sinai Health System
**Publication Date**: 2025-11-18
**Description**: Press release about collaboration with NVIDIA and ARC Innovation

### [IPGaia and the Icahn School of Medicine at Mount Sinai Announce Comprehensive Collaborative Research and Development Agreement](https://www.mountsinai.org/about/newsroom/2024/ipgaia-and-the-icahn-school-of-medicine-at-mount-sinai-announce-comprehensive-collaborative-research-and-development-agreement)
**Type**: press_release
**Relevance**: secondary
**Category**: partnership
**Relationship Description**: Press release about partnership with IPGaia Inc.
**Publisher**: Mount Sinai Health System
**Publication Date**: 2024-09-10
**Description**: Press release about partnership with IPGaia Inc.

### [Health and Medical AI Research | Icahn School of Medicine](https://icahn.mssm.edu/about/artificial-intelligence/research)
**Type**: website
**Relevance**: secondary
**Category**: website
**Relationship Description**: Overview of AI research initiatives at Icahn School of Medicine
**Publisher**: Icahn School of Medicine at Mount Sinai
**Description**: Overview of AI research initiatives at Icahn School of Medicine

### [AI Small Molecule Drug Discovery Center | Icahn School of Medicine](https://icahn.mssm.edu/research/ai-drug-discovery-center)
**Type**: website
**Relevance**: primary
**Category**: website
**Relationship Description**: Official center webpage with mission, leadership, and research focus
**Publisher**: Icahn School of Medicine at Mount Sinai
**Description**: Official center webpage with mission, leadership, and research focus

### [Mount Sinai Launches AI Small Molecule Drug Discovery Center](https://www.mountsinai.org/about/newsroom/2025/mount-sinai-launches-ai-small-molecule-drug-discovery-center)
**Type**: press_release
**Relevance**: primary
**Category**: announcement
**Relationship Description**: Official press release announcing the launch of the AI Small Molecule Drug Discovery Center
**Publisher**: Mount Sinai Health System
**Publication Date**: 2025-04-02
**Description**: Official press release announcing the launch of the AI Small Molecule Drug Discovery Center

## Financials

### grant
**Amount**: $5,000,000 USD
**Amount (Numeric)**: 5000000
**Funding Date**: 2023-11-15
**Period**: Not specified
**Source**: National Cancer Institute (NCI), NIH
**Funding Type**: Government Grant
**Description**: Create a center for discovery and development of new targets for cancer therapy
**Details**:
```yaml
note: Grant awarded to Icahn School of Medicine, may support related drug discovery infrastructure and cancer research programs
funder: National Cancer Institute (NCI), NIH
purpose: Create a center for discovery and development of new targets for cancer therapy
source_url: "https://www.mountsinai.org/about/newsroom/2023/icahn-school-of-medicine-at-mount-sinai-secures-five-million-nih-grant-for-cutting-edge-cancer-target-discovery-and-development-center"
```

### grant
**Amount**: $8,000,000 USD
**Amount (Numeric)**: 8000000
**Funding Date**: 2025-09-17
**Period**: Not specified
**Source**: DataPhilanthropy
**Funding Type**: Private Foundation Grant
**Description**: Establish a translational center dedicated to the development of treatments for cerebral small vessel diseases, including CADASIL
**Details**:
```yaml
scope: "Supports center's research programs focused on neurological diseases, including CADASIL and related brain disorders"
funder: DataPhilanthropy
purpose: Establish a translational center dedicated to the development of treatments for cerebral small vessel diseases, including CADASIL
source_url: "https://www.mountsinai.org/about/newsroom/2025/mount-sinai-receives-8-million-from-dataphilanthropy-to-accelerate-drug-discovery-for-cadasil-and-related-brain-disorders"
```

## Events

### Partnership with IPGaia Inc.
**Date**: 2024-08-07
**Type**: partnership
**Description**: Comprehensive Collaborative Research and Development Agreement signed with IPGaia Inc. to incorporate promising drug target leads from Mount Sinai into IPGaia's drug discovery platform
**Details**:
```yaml
type: Partnership
scope: Drug target identification and development
significance: Precursor partnership before center launch
announcement_date: 2024-09-10
```

### Official Launch of AI Small Molecule Drug Discovery Center
**Date**: 2025-04-02
**Type**: launch
**Description**: Official launch of the AI Small Molecule Drug Discovery Center at Icahn School of Medicine at Mount Sinai
**Details**:
```yaml
type: Launch
announcement: "Press release announcing the center's mission to integrate AI with traditional drug discovery methods"
```

### DataPhilanthropy $8 Million Grant
**Date**: 2025-09-17
**Type**: funding
**Description**: Received $8 million grant from DataPhilanthropy to establish a translational center for CADASIL and related brain disorders
**Details**:
```yaml
type: Funding
amount: $8,000,000
currency: USD
significance: "Major external funding supporting center's research programs"
```

### NVIDIA and ARC Innovation Collaboration
**Date**: 2025-11-18
**Type**: partnership
**Description**: Three-year collaboration announced with ARC Innovation at Sheba Medical Center and NVIDIA to harness AI for genomic discovery using large language model technology
**Details**:
```yaml
type: Partnership
scope: Genomic discovery using AI and LLM technology
duration: 3 years
significance: "Expands center's AI capabilities and international partnerships"
```

## Partnerships

### research
**Date**: 2025-11-18
**Focus**: Genomic discovery using AI and LLM technology
**Description**: Collaboration to harness artificial intelligence for genomic discovery through the application of large language model technology. Aims to decode unexplored parts of the human genome.
**Partner Organizations**:
- ARC Innovation at Sheba Medical Center (partner)
- NVIDIA (partner)
**Details**:
```yaml
type: Three-year Collaboration
scope: Genomic discovery using AI and LLM technology
partner: ARC Innovation at Sheba Medical Center and NVIDIA
duration: 3 years
source_url: "https://www.mountsinai.org/about/newsroom/2025/arc-at-sheba-medical-center-and-mount-sinai-launch-collaboration-with-nvidia-to-crack-the-hidden-code-of-the-human-genome-through-ai"
```

### research
**Date**: 2024-08-07
**Focus**: Drug target identification and development
**Description**: Comprehensive Collaborative Research and Development Agreement to incorporate promising drug target leads from Icahn Mount Sinai into IPGaia's drug discovery platform. Partnership enables integration of Mount Sinai's target identification capabilities with IPGaia's discovery platform.
**Partner Organizations**:
- IPGaia Inc. (partner)
**Details**:
```yaml
type: Collaborative Research and Development Agreement
scope: Drug target identification and development
partner: IPGaia Inc.
source_url: "https://www.mountsinai.org/about/newsroom/2024/ipgaia-and-the-icahn-school-of-medicine-at-mount-sinai-announce-comprehensive-collaborative-research-and-development-agreement"
announcement_date: 2024-09-10
```
